This ADC product is comprised of an anti-MS4A1 monoclonal antibody (rituximab) conjugated via a VC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within th
* VAT and and shipping costs not included. Errors and price changes excepted